Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297891 | 0.75 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL22065130 | 0.70 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL21720386 | 0.70 | ESR1 (0.30) | ESR1ESR2 | |
| SCHEMBL22624088 | 0.67 | FAAH (0.34) | — | |
| SCHEMBL21720638 | 0.67 | — | — | |
| SCHEMBL21720343 | 0.67 | ALDH1A1 (0.33) | — | |
| SCHEMBL21554005 | 0.67 | ESR1 (0.33) | ESR1ESR2 | |
| SCHEMBL21720569 | 0.66 | — | — | |
| SCHEMBL21720384 | 0.66 | — | — | |
| SCHEMBL21794041 | 0.66 | SMN1; SMN2 (0.34) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836770-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190225620-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225620-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, IL2, IFNAR1 | ESR1 4755/4885ESR2 1856/4885 |
| US-10836770-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses | TYK2, IL2, IFNAR1 | ESR1 4358/4885ESR2 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.